Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHL
China Mobile Limited
CHL
|
+$4.79M |
| 2 |
Kinross Gold
KGC
|
+$3.92M |
| 3 |
Stride
LRN
|
+$2.85M |
| 4 |
World Kinect Corp
WKC
|
+$2.72M |
| 5 |
Reinsurance Group of America
RGA
|
+$2.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tanger
SKT
|
+$3.39M |
| 2 |
Capri Holdings
CPRI
|
+$3.29M |
| 3 |
Children's Place
PLCE
|
+$3.19M |
| 4 |
DHIL
Diamond Hill
DHIL
|
+$2.37M |
| 5 |
WW
WW International
WW
|
+$1.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 6.83% |
| 2 | Consumer Discretionary | 6.06% |
| 3 | Technology | 5.36% |
| 4 | Financials | 5.07% |
| 5 | Materials | 4.07% |
Similar funds
Invenomic Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Invenomic Capital Management held 189 positions worth $392M, up 116% from $182M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Invenomic Capital Management deployed $89.7M of net new capital in Q4 2020, opening 48 new positions and adding to 30 existing holdings. Its largest new stake was China Mobile Limited: 154,826 shares worth $4.42M.
By sector, the portfolio is most concentrated in Industrials at 6.8% of assets, down from 10% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Tanger, an estimated $3.39M trimmed.
- Invenomic Capital Management's largest Q4 2020 buy was China Mobile Limited: 154,826 shares worth $4.42M.
- Invenomic Capital Management added most to Kinross Gold in Q4 2020, an estimated $3.92M increase.
- Invenomic Capital Management's biggest Q4 2020 reduction was Tanger, cutting an estimated $3.39M.
- Invenomic Capital Management fully exited F5 in Q4 2020, selling an estimated $1.62M.
- Invenomic Capital Management's ten largest holdings make up 59% of its $392M portfolio in Q4 2020.
- Invenomic Capital Management opened 48 new positions and closed 47 in Q4 2020.
- Invenomic Capital Management's portfolio value rose 116% quarter-over-quarter to $392M.
Based on Invenomic Capital Management's 13F filing for Q4 2020, filed 17 Feb 2021.